A John Rush

List of Publications by Year
in descending order

487 papers	64,223 citations	813 118 h-index	962 238 g-index
496 all docs	496 docs citations	496 times ranked	33954 citing authors

#	Article	IF	Citations
1	The Epidemiology of Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2003, 289, 3095.	7.4	6,692
2	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1905-1917.	7.2	4,241
3	Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. American Journal of Psychiatry, 2006, 163, 28-40.	7.2	3,206
4	The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 2003, 54, 573-583.	1.3	2,981
5	A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression. New England Journal of Medicine, 2000, 342, 1462-1470.	27.0	1,188
6	Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression. New England Journal of Medicine, 2006, 354, 1231-1242.	27.0	934
7	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Contemporary Clinical Trials, 2004, 25, 119-142.	1.9	898
8	Medication Augmentation after the Failure of SSRIs for Depression. New England Journal of Medicine, 2006, 354, 1243-1252.	27.0	897
9	The inventory for depressive symptomatology (IDS): Preliminary findings. Psychiatry Research, 1986, 18, 65-87.	3.3	794
10	Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report. American Journal of Psychiatry, 2008, 165, 342-351.	7.2	741
11	Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14293-14296.	7.1	729
12	Axis I Psychiatric Comorbidity and Its Relationship to Historical Illness Variables in 288 Patients With Bipolar Disorder. American Journal of Psychiatry, 2001, 158, 420-426.	7.2	611
13	Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. Neuropsychopharmacology, 2006, 31, 1841-1853.	5.4	572
14	The STAR*D project results: A comprehensive review of findings. Current Psychiatry Reports, 2007, 9, 449-459.	4.5	554
15	Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial. Biological Psychiatry, 2005, 58, 347-354.	1.3	542
16	Remissions in Maternal Depression and Child Psychopathology. JAMA - Journal of the American Medical Association, 2006, 295, 1389.	7.4	539
17	A Comparison of Lithium and T_3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1519-1530.	7.2	526
18	What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. Psychiatric Services, 2009, 60, 1439-1445.	2.0	508

#	Article	IF	Citations
19	Estimating Individualized Treatment Rules Using Outcome Weighted Learning. Journal of the American Statistical Association, 2012, 107, 1106-1118.	3.1	472
20	Vagus Nerve Stimulation (VNSâ„¢) for Treatment-Resistant Depression Efficacy, Side Effects, and Predictors of Outcome. Neuropsychopharmacology, 2001, 25, 713-728.	5.4	456
21	Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STARâˆ—D) study. Psychiatric Clinics of North America, 2003, 26, 457-494.	1.3	456
22	Implementing Evidence-Based Practices for Persons With Severe Mental Illnesses. Psychiatric Services, 2001, 52, 45-50.	2.0	445
23	Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment. American Journal of Human Genetics, 2006, 78, 804-814.	6.2	434
24	Effect of Age at Onset on the Course of Major Depressive Disorder. American Journal of Psychiatry, 2007, 164, 1539-1546.	7.2	393
25	ECT Remission Rates in Psychotic Versus Nonpsychotic Depressed Patients: A Report from CORE. Journal of ECT, 2001, 17, 244-253.	0.6	384
26	Gender differences in depression: Findings from the STAR*D study. Journal of Affective Disorders, 2005, 87, 141-150.	4.1	359
27	Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychological Medicine, 2004, 34, 1299-1308.	4.5	352
28	Early physical and sexual abuse associated with an adverse course of bipolar illness. Biological Psychiatry, 2002, 51, 288-297.	1.3	350
29	Speed of Response and Remission in Major Depressive Disorder With Acute Electroconvulsive Therapy (ECT). Journal of Clinical Psychiatry, 2004, 65, 485-491.	2.2	346
30	Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study. Biological Psychiatry, 2005, 58, 355-363.	1.3	345
31	An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report. Biological Psychiatry, 2006, 59, 493-501.	1.3	344
32	Treating Major Depression in Primary Care Practice. Archives of General Psychiatry, 1998, 55, 1121.	12.3	341
33	Methods to Improve Diagnostic Accuracy in a Community Mental Health Setting. American Journal of Psychiatry, 2000, 157, 1599-1605.	7.2	338
34	Effect Size of Lithium, Divalproex Sodium, and Carbamazepine in Children and Adolescents With Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2000, 39, 713-720.	0.5	332
35	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. American Journal of Psychiatry, 2011, 168, 689-701.	7.2	329
36	The Inventory of Depressive Symptomatology (IDS): Clinician (IDSâ€C) and Selfâ€Report (IDSâ€SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research, 2000, 9, 45-59.	2.1	328

#	Article	IF	Citations
37	Two-Year Outcome of Vagus Nerve Stimulation (VNS) for Treatment of Major Depressive Episodes. Journal of Clinical Psychiatry, 2005, 66, 1097-1104.	2.2	323
38	A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression. Biological Psychiatry, 2005, 58, 364-373.	1.3	319
39	Onset and Persistence of Postpartum Depression in an Inner-City Maternal Health Clinic System. American Journal of Psychiatry, 2001, 158, 1856-1863.	7.2	312
40	Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1531-1541.	7.2	300
41	STAR*D: What Have We Learned?. American Journal of Psychiatry, 2007, 164, 201-204.	7.2	300
42	Cognitive patterns in symptomatic and remitted unipolar major depression.. Journal of Abnormal Psychology, 1984, 93, 31-40.	1.9	298
43	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 739-752.	7.2	297
44	The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs. Journal of Clinical Psychiatry, 2002, 63, 963-971.	2.2	291
45	Hippocampal Remodeling and Damage by Corticosteroids Implications for Mood Disorders. Neuropsychopharmacology, 1999, 21, 474-484.	5.4	285
46	Clinical Results for Patients With Major Depressive Disorder in theTexas Medication Algorithm Project. Archives of General Psychiatry, 2004, 61, 669.	12.3	284
47	A Genomewide Association Study Points to Multiple Loci That Predict Antidepressant Drug Treatment Outcome in Depression. Archives of General Psychiatry, 2009, 66, 966.	12.3	284
48	Sertraline as a first-line treatment for cholestatic pruritus. Hepatology, 2007, 45, 666-674.	7.3	274
49	The Treatment of Chronic Depression, Part 3. Journal of Clinical Psychiatry, 1998, 59, 608-619.	2.2	266
50	Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biological Psychiatry, 2002, 51, 280-287.	1.3	262
51	Relief of Expressed Suicidal Intent by ECT: A Consortium for Research in ECT Study. American Journal of Psychiatry, 2005, 162, 977-982.	7.2	257
52	The FKBP5-Gene in Depression and Treatment Response—an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biological Psychiatry, 2008, 63, 1103-1110.	1.3	240
53	Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biological Psychiatry, 2004, 55, 538-545.	1.3	239
54	Randomized, Placebo-Controlled Trial of Mixed Amphetamine Salts for Symptoms of Comorbid ADHD in Pediatric Bipolar Disorder After Mood Stabilization With Divalproex Sodium. American Journal of Psychiatry, 2005, 162, 58-64.	7.2	238

#	Article	IF	Citations
55	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1161-1172.	7.2	233
56	Self-Rated Global Measure of the Frequency, Intensity, and Burden of Side Effects. Journal of Psychiatric Practice, 2006, 12, 71-79.	0.7	227
57	Psychotherapy and Medication in the Treatment of Adult and Geriatric Depression. Journal of Clinical Psychiatry, 2005, 66, 455-468.	2.2	227
58	15 Years of Clinical Experience With Bupropion HCl. Primary Care Companion To the Journal of Clinical Psychiatry, 2005, 7, 106-13.	0.6	225
59	GABAB Receptors, Schizophrenia and Sleep Dysfunction. CNS Drugs, 2009, PAP, 627-47.	5.9	220
60	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. American Journal of Psychiatry, 2013, 170, 207-217.	7.2	216
61	Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. Journal of Affective Disorders, 2005, 87, 43-55.	4.1	210
62	Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Comprehensive Psychiatry, 2008, 49, 238-246.	3.1	209
63	Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report. American Journal of Psychiatry, 2009, 166, 599-607.	7.2	209
64	Association Between a Functional Serotonin Transporter Promoter Polymorphism and Citalopram Treatment in Adult Outpatients With Major Depression. Archives of General Psychiatry, 2007, 64, 783.	12.3	208
65	Does psychosocial functioning improve independent of depressive symptoms? a comparison of nefazodone, psychotherapy, and their combination. Biological Psychiatry, 2002, 51, 123-133.	1.3	204
66	Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression. American Journal of Psychiatry, 2007, 164, 1530-1538.	7.2	203
67	Polysomnographic Findings in Recently Drug-Free and Clinically Remitted Depressed Patients. Archives of General Psychiatry, 1986, 43, 878.	12.3	193
68	Association Between Major Depressive Episodes in Patients With Chronic Kidney Disease and Initiation of Dialysis, Hospitalization, or Death. JAMA - Journal of the American Medical Association, 2010, 303, 1946.	7.4	193
69	MAOIs in the Contemporary Treatment of Depression. Neuropsychopharmacology, 1995, 12, 185-219.	5.4	190
70	Cross-Disorder Genomewide Analysis of Schizophrenia, Bipolar Disorder, and Depression. American Journal of Psychiatry, 2010, 167, 1254-1263.	7.2	190
71	Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort. American Journal of Psychiatry, 2007, 164, 1181-1188.	7.2	189
72	Prospective, Long-Term, Multicenter Study of the Naturalistic Outcomes of Patients With Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2006, 67, 688-695.	2.2	189

#	Article	IF	Citations
73	The Montgomery Ã„sberg and the Hamilton ratings of depression: A comparison of measures. European Neuropsychopharmacology, 2006, 16, 601-611.	0.7	183
74	The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophrenia Research, 2008, 100, 60-69.	2.0	179
75	Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Comprehensive Psychiatry, 2003, 44, 263-269.	3.1	175
76	Texas Medication Algorithm Project. Journal of Clinical Psychiatry, 1998, 59, 345-351.	2.2	174
77	The Texas Medication Algorithm Project. Journal of Clinical Psychiatry, 1999, 60, 142-156.	2.2	174
78	Research issues in the study of difficult-to-treat depression. Biological Psychiatry, 2003, 53, 743-753.	1.3	169
79	Children of Depressed Mothers 1 Year After the Initiation of Maternal Treatment: Findings From the STAR*D-Child Study. American Journal of Psychiatry, 2008, 165, 1136-1147.	7.2	169
80	The Influence of Age on the Response of Major Depression to Electroconvulsive Therapy: A C.O.R.E. Report. American Journal of Geriatric Psychiatry, 2001, 9, 382-390.	1.2	167
81	Acupuncture: a promising treatment for depression during pregnancy. Journal of Affective Disorders, 2004, 83, 89-95.	4.1	167
82	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1161.	7.2	167
83	The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia. Journal of Clinical Psychiatry, 2004, 65, 500-508.	2.2	165
84	Clinical and Demographic Features of Atypical Depression in Outpatients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2005, 66, 1002-1011.	2.2	165
85	Sex differences in response to citalopram: A STARâˆ'D report. Journal of Psychiatric Research, 2009, 43, 503-511.	3.1	164
86	International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials, 2011, 12, 4.	1.6	163
87	Prevalence of Major Depressive Episode in CKD. American Journal of Kidney Diseases, 2009, 54, 424-432.	1.9	162
88	A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research, 2005, 133, 129-133.	3.3	159
89	The Dexamethasone Suppression Test in Patients With Mood Disorders. Journal of Clinical Psychiatry, 1996, 57, 470-484.	2.2	158
90	Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents. American Journal of Psychiatry, 2008, 165, 459-467.	7.2	156

#	Article	IF	Citations
91	Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy. JAMA Psychiatry, 2015, 72, 1102.	11.0	155
92	Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology, 2017, 78, 105-113.	2.7	155
93	A Descriptive Analysis of Minor Depression. American Journal of Psychiatry, 2002, 159, 637-643.	7.2	154
94	Selecting Among Second-Step Antidepressant Medication Monotherapies. Archives of General Psychiatry, 2008, 65, 870.	12.3	152
95	Improving the Prediction of Treatment Response in Depression: <i>Integration of Clinical, Cognitive, Psychophysiological, Neuroimaging, and Genetic Measures</i>. CNS Spectrums, 2008, 13, 1066-1086.	1.2	150
96	Children of Depressed Mothers 1 Year After Remission of Maternal Depression: Findings From the STAR*D-Child Study. American Journal of Psychiatry, 2011, 168, 593-602.	7.2	149
97	What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension. Canadian Journal of Psychiatry, 2006, 51, 823-835.	1.9	148
98	Fluoxetine in child and adolescent depression: Acute and maintenance treatment. Depression and Anxiety, 1998, 7, 32-39.	4.1	147
99	Measurement-Based Care in Psychiatric Practice. Journal of Clinical Psychiatry, 2011, 72, 1136-1143.	2.2	142
100	Genome-Wide Association Study of Suicide Attempts in Mood Disorder Patients. American Journal of Psychiatry, 2010, 167, 1499-1507.	7.2	140
101	Chronic Depression. Archives of General Psychiatry, 2005, 62, 513.	12.3	139
102	Bupropion and Naltrexone in Methamphetamine Use Disorder. New England Journal of Medicine, 2021, 384, 140-153.	27.0	139
103	Factors Associated With Health-Related Quality of Life Among Outpatients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2006, 67, 185-195.	2.2	139
104	Dropouts versus completers among chronically depressed outpatients. Journal of Affective Disorders, 2007, 97, 197-202.	4.1	138
105	Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. American Journal of Psychiatry, 2015, 172, 743-750.	7.2	138
106	Relationship between objective and subjective sleep measures in depressed patients and healthy controls. Depression and Anxiety, 1997, 5, 97-102.	4.1	136
107	Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice. Psychotherapy and Psychosomatics, 2006, 75, 139-153.	8.8	136
108	Dream recall and major depression: A preliminary report.. Dreaming, 1995, 5, 189-198.	0.5	135

#	Article	IF	Citations
109	Maximizing the Adequacy of Medication Treatment in Controlled Trials and Clinical Practice: STAR*D Measurement-Based Care. Neuropsychopharmacology, 2007, 32, 2479-2489.	5.4	135
110	Use of Bupropion in Combination with Serotonin Reuptake Inhibitors. Biological Psychiatry, 2006, 59, 203-210.	1.3	132
111	The Treatment of Chronic Depression, Part 2. Journal of Clinical Psychiatry, 1998, 59, 598-607.	2.2	132
112	Predictors of Attrition During Initial (Citalopram) Treatment for Depression: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 1189-1197.	7.2	129
113	Association Between Treatment-Emergent Suicidal Ideation With Citalopram and Polymorphisms Near Cyclic Adenosine Monophosphate Response Element Binding Protein in the STAR*D Study. Archives of General Psychiatry, 2007, 64, 689.	12.3	128
114	Benzodiazepines as antidepressants: Does GABA play a role in depression?. Biological Psychiatry, 1995, 38, 578-591.	1.3	126
115	Algorithms and Collaborative-care Systems for Depression: Are They Effective and Why?. Biological Psychiatry, 2006, 59, 1029-1038.	1.3	125
116	Insomnia in Patients With Depression: <i>A STAR*D Report</i>. CNS Spectrums, 2010, 15, 394-404.	1.2	125
117	Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome. Drug and Alcohol Dependence, 2009, 99, 248-260.	3.2	124
118	Concise Health Risk Tracking Scale. Journal of Clinical Psychiatry, 2011, 72, 757-764.	2.2	124
119	Double-blind Switch Study of Imipramine or Sertraline Treatment of Antidepressant-Resistant Chronic Depression. Archives of General Psychiatry, 2002, 59, 233.	12.3	123
120	Children of Currently Depressed Mothers. Journal of Clinical Psychiatry, 2006, 67, 126-136.	2.2	123
121	Cognitive-Behavioral Analysis System of Psychotherapy as a Maintenance Treatment for Chronic Depression.. Journal of Consulting and Clinical Psychology, 2004, 72, 681-688.	2.0	122
122	Factors that differentiate early vs. later onset of major depression disorder. Psychiatry Research, 2004, 129, 127-140.	3.3	121
123	The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment. Journal of Psychiatric Research, 2015, 61, 1-12.	3.1	121
124	Depression and Chronic Low Back Pain. Spine, 2000, 25, 2566-2571.	2.0	119
125	Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder. Archives of General Psychiatry, 2010, 68, 351.	12.3	118
126	The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 1999, 38, 1442-1454.	0.5	115

#	Article	IF	Citations
127	Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients. Neuropsychopharmacology, 2005, 30, 405-416.	5.4	115
128	The Texas Medication Algorithm Project (TMAP) Schizophrenia Algorithms. Journal of Clinical Psychiatry, 1999, 60, 649-657.	2.2	115
129	Validation of Depression Screening Scales in Patients With CKD. American Journal of Kidney Diseases, 2009, 54, 433-439.	1.9	111
130	Depression, IV: STAR*D Treatment Trial for Depression. American Journal of Psychiatry, 2003, 160, 237-237.	7.2	109
131	Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. General Hospital Psychiatry, 2004, 26, 421-429.	2.4	109
132	Recurrence of Major Depressive Disorder in Hospitalized Children and Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, 36, 785-792.	0.5	108
133	Validity of Electronically Monitored Medication Adherence and Conventional Adherence Measures in Schizophrenia. Psychiatric Services, 2007, 58, 844-847.	2.0	108
134	Comparison of Self-Report and Clinician Ratings on Two Inventories of Depressive Symptomatology. Psychiatric Services, 2006, 57, 829-837.	2.0	106
135	Clinical and Demographic Factors Associated With DSM-IV Melancholic Depression. Annals of Clinical Psychiatry, 2006, 18, 91-98.	0.6	105
136	Association of Polymorphisms in Genes Regulating the Corticotropin-Releasing Factor System With Antidepressant Treatment Response. Archives of General Psychiatry, 2010, 67, 369.	12.3	105
137	Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents. International Journal of Methods in Psychiatric Research, 2010, 19, 185-194.	2.1	104
138	Increase in Work Productivity of Depressed Individuals With Improvement in Depressive Symptom Severity. American Journal of Psychiatry, 2013, 170, 633-641.	7.2	104
139	Simultaneous rTMS and psychotherapy in major depressive disorder: Clinical outcomes and predictors from a large naturalistic study. Brain Stimulation, 2018, 11, 337-345.	1.6	104
140	Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenetics and Genomics, 2009, 19, 666-674.	1.5	103
141	Medication Treatment for the Severely and Persistently Mentally Ill. Journal of Clinical Psychiatry, 1999, 60, 284-291.	2.2	102
142	A Cognitive–Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D Trial. Neuropsychopharmacology, 2015, 40, 1332-1342.	5.4	101
143	Low plasma γ-aminobutyric acid levels in male patients with depression. Biological Psychiatry, 1992, 32, 354-363.	1.3	100
144	Low Plasma GABA Is a Trait-Like Marker for Bipolar Illness. Neuropsychopharmacology, 1993, 9, 125-132.	5.4	100

#	Article	IF	Citations
145	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence. JAMA - Journal of the American Medical Association, 2017, 318, 1876.	7.4	99
146	The Effects of Nefazodone on Sleep Architecture in Depression. Neuropsychopharmacology, 1994, 10, 123-127.	5.4	97
147	Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disorders, 2001, 3, 259-265.	1.9	97
148	The Stanley Foundation Bipolar Network. British Journal of Psychiatry, 2001, 178, s169-s176.	2.8	96
149	Symptom features of postpartum depression: are they distinct?. Depression and Anxiety, 2008, 25, 20-26.	4.1	96
150	The Cost Consequences of Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2004, 65, 341-347.	2.2	96
151	The Effects of Psychotherapy, Nefazodone, and Their Combination on Subjective Assessment of Disturbed Sleep in Chronic Depression. Sleep, 2003, 26, 130-136.	1.1	95
152	Presenting characteristics of depressed outpatients as a function of recurrence: Preliminary findings from the STAR*D clinical trial. Journal of Psychiatric Research, 2006, 40, 59-69.	3.1	95
153	Brief Psychiatric Rating Scale Expanded Version: How do new items affect factor structure?. Psychiatry Research, 2005, 135, 217-228.	3.3	94
154	One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biological Psychiatry, 2004, 56, 46-53.	1.3	93
155	Major Depression Symptoms in Primary Care and Psychiatric Care Settings: A Cross-Sectional Analysis. Annals of Family Medicine, 2007, 5, 126-134.	1.9	92
156	Durability of antidepressant response to vagus nerve stimulation (VNS). International Journal of Neuropsychopharmacology, 2007, 10, 817-26.	2.1	92
157	Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*D. Journal of General Internal Medicine, 2008, 23, 551-560.	2.6	92
158	Pharmacogenetic Analysis of Genes Implicated in Rodent Models of Antidepressant Response: Association of TREK1 and Treatment Resistance in the STAR*D Study. Neuropsychopharmacology, 2008, 33, 2810-2819.	5.4	92
159	Texas Medication Algorithm Project, Phase 3 (TMAP-3). Journal of Clinical Psychiatry, 2003, 64, 357-369.	2.2	92
160	Response to a Selective Serotonin Reuptake Inhibitor (Citalopram) in Major Depressive Disorder With Melancholic Features. Journal of Clinical Psychiatry, 2008, 69, 1847-1855.	2.2	91
161	Group versus individual cognitive therapy: A pilot study. Cognitive Therapy and Research, 1981, 5, 95-103.	1.9	88
162	Genetic and Clinical Predictors of Sexual Dysfunction in Citalopram-Treated Depressed Patients. Neuropsychopharmacology, 2009, 34, 1819-1828.	5.4	88

#	Article	IF	Citations
163	Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STARâŽD study. Journal of Affective Disorders, 2009, 117, 63-73.	4.1	88
164	Implementing practice guidelines for depression: Applying a new framework to an old problem. General Hospital Psychiatry, 2002, 24, 35-42.	2.4	87
165	Methodological Challenges in Constructing Effective Treatment Sequences for Chronic Psychiatric Disorders. Neuropsychopharmacology, 2007, 32, 257-262.	5.4	87
166	Do thinking patterns predict depressive symptoms?. Cognitive Therapy and Research, 1986, 10, 225-235.	1.9	85
167	A Randomized Trial of Citalopram versus Placebo in Outpatients with Asthma and Major Depressive Disorder: A Proof of Concept Study. Biological Psychiatry, 2005, 58, 865-870.	1.3	84
168	Texas Medication Algorithm Project, Phase 3 (TMAP-3). Journal of Clinical Psychiatry, 2003, 64, 370-382.	2.2	84
169	Substance Use Disorder Comorbidity in Major Depressive Disorder: A Confirmatory Analysis of the STAR*D Cohort. American Journal on Addictions, 2006, 15, 278-285.	1.4	83
170	A Randomized, Doubleâ€Blind, Placeboâ€Controlled Pilot Study of Naltrexone in Outpatients With Bipolar Disorder and Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2009, 33, 1863-1869.	2.4	83
171	A Multicenter, Double-Blind Comparison of the Effects of Nefazodone and Fluoxetine on Sleep Architecture and Quality of Sleep in Depressed Outpatients. Journal of Clinical Psychopharmacology, 1997, 17, 161-168.	1.4	83
172	Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment. Journal of Youth and Adolescence, 2008, 37, 906-916.	3.5	81
173	Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatrica Scandinavica, 2009, 119, 282-289.	4.5	81
174	Customizing treatment to the patient: Adaptive treatment strategies. Drug and Alcohol Dependence, 2007, 88, S1-S3.	3.2	80
175	Sleep polysomnography as a predictor of recurrence in children and adolescents with major depressive disorder. International Journal of Neuropsychopharmacology, 2001, 4, 159-68.	2.1	79
176	Short-Term Psychotherapy of Depressive Disorders. Psychiatry (New York), 1994, 57, 115-132.	0.7	78
177	High Frequency EEG Activity during Sleep: Characteristics in Schizophrenia and Depression. Clinical EEG and Neuroscience, 2005, 36, 25-35.	1.7	78
178	Randomized, Placebo-Controlled Trial of Fluoxetine for Acute Treatment of Minor Depressive Disorder. American Journal of Psychiatry, 2004, 161, 1864-1871.	7.2	77
179	The Texas Medication Algorithm Project: Clinical Results for Schizophrenia. Schizophrenia Bulletin, 2004, 30, 627-647.	4.3	77
180	Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries. Journal of Psychiatric Research, 2005, 39, 481-488.	3.1	74

#	Article	IF	Citations
181	Temporal Characteristics of Delta Activity During NREM Sleep in Depressed Outpatients and Healthy Adults: Group and Sex Effects. Sleep, 2000, 23, 1-11.	1.1	73
182	Pain in depression: STAR*D study findings. Journal of Psychosomatic Research, 2007, 63, 113-122.	2.6	73
183	Clinical differences among depressed patients with and without a history of suicide attempts: Findings from the STARâZD trial. Journal of Affective Disorders, 2007, 97, 77-84.	4.1	71
184	Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug and Alcohol Dependence, 2010, 107, 161-170.	3.2	71
185	Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. American Journal of Psychiatry, 2016, 173, 107-111.	7.2	71
186	Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biological Psychiatry, 1997, 41, 915-928.	1.3	70
187	VAGUS NERVE STIMULATION. Psychiatric Clinics of North America, 2000, 23, 757-783.	1.3	70
188	Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology, 2007, 32, 843-853.	2.7	70
189	Randomized, Placebo-Controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biological Psychiatry, 2003, 54, 806-817.	1.3	69
190	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results. Psychiatric Services, 2009, 60, 1446-1457.	2.0	69
191	What predicts attrition in second step medication treatments for depression?: a STAR*D Report. International Journal of Neuropsychopharmacology, 2009, 12, 459.	2.1	69
192	Pharmacogenomicsâ€Driven Prediction of Antidepressant Treatment Outcomes: A Machineâ€Learning Approach With Multiâ€trial Replication. Clinical Pharmacology and Therapeutics, 2019, 106, 855-865.	4.7	69
193	Acceptability of Second-Step Treatments to Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 753-760.	7.2	68
194	The symptomâ€specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data metaâ€analysis. World Psychiatry, 2019, 18, 183-191.	10.4	68
195	Family history of mood disorder and characteristics of major depressive disorder: A STARˆ—D (sequenced treatment alternatives to relieve depression) study. Journal of Psychiatric Research, 2007, 41, 214-221.	3.1	67
196	Treating Depression to Remission. Psychiatric Annals, 1995, 25, 704-709.	0.1	67
197	Depression in Asthma: Prevalence and Clinical Implications. Primary Care Companion To the Journal of Clinical Psychiatry, 2000, 02, 153-158.	0.6	67
198	Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial. European Neuropsychopharmacology, 2012, 22, 183-199.	0.7	65

#	Article	IF	Citations
199	Prevalence and Clinical Correlates of Irritability in Major Depressive Disorder. Journal of Clinical Psychiatry, 2005, 66, 159-166.	2.2	65
200	Clinical Practice Guidelines. Archives of General Psychiatry, 1993, 50, 483.	12.3	64
201	The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). Journal of Psychiatric Research, 2019, 113, 125-136.	3.1	64
202	A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. Medical Devices: Evidence and Research, 2013, 6, 17.	0.8	63
203	The Effects of Fluoxetine on the Polysomnogram of Depressed Outpatients: A Pilot Study. Neuropsychopharmacology, 1994, 10, 85-91.	5.4	62
204	Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disorders, 2002, 4, 283-289.	1.9	62
205	A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. General Hospital Psychiatry, 2005, 27, 87-96.	2.4	62
206	A Trial of Compliance Therapy in Outpatients With Schizophrenia or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2005, 66, 997-1001.	2.2	62
207	Tridimensional personality questionnaire and serotonin in bulimia nervosa. Psychiatry Research, 1993, 48, 9-15.	3.3	61
208	Vagus nerve stimulation (VNS): utility in neuropsychiatric disorders. International Journal of Neuropsychopharmacology, 2003, 6, 73-83.	2.1	61
209	Remission of Maternal Depression: Relations to Family Functioning and Youth Internalizing and Externalizing Symptoms. Journal of Clinical Child and Adolescent Psychology, 2008, 37, 714-724.	3.4	60
210	Depressive Symptoms by Self-Report in Adolescence: Phase I of the Development of a Questionnaire for Depression by Self-Report. Journal of Child Neurology, 1990, 5, 114-121.	1.4	59
211	Association of Depressive Symptoms with Hippocampal Volume in 1936 Adults. Neuropsychopharmacology, 2014, 39, 770-779.	5.4	59
212	Concise Associated Symptoms Tracking Scale. Journal of Clinical Psychiatry, 2011, 72, 765-774.	2.2	58
213	Cognitive Therapy of Depression and Suicide. American Journal of Psychotherapy, 1978, 32, 201-219.	1.2	57
214	Effects of Fluoxetine on the Polysomnogram in Outpatients with Major Depression. Neuropsychopharmacology, 1999, 20, 447-459.	5.4	57
215	An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. Schizophrenia Research, 2006, 81, 311-316.	2.0	57
216	Comorbid disorders in patients with bipolar disorder and concomitant substance dependence. Journal of Affective Disorders, 2007, 102, 281-287.	4.1	56

#	Article	IF	Citations
217	Clinical Features of Depression in Outpatients With and Without Co-Occurring General Medical Conditions in STAR*D. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 7-15.	0.6	56
218	Ethnicity/Race and Outcome in the Treatment of Depression. Medical Care, 2007, 45, 1043-1051.	2.4	54
219	Alprazolam vs Amitriptyline in Depressions With Reduced REM Latencies. Archives of General Psychiatry, 1985, 42, 1154.	12.3	53
220	Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in Major Depressive Disorder. EBioMedicine, 2015, 2, 37-45.	6.1	53
221	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. Translational Psychiatry, 2019, 9, 173.	4.8	53
222	The Texas Medication Algorithm Project: Development and Implementation of the Schizophrenia Algorithm. Psychiatric Services, 1999, 50, 69-74.	2.0	53
223	Do Bupropion SR and Sertraline Differ in Their Effects on Anxiety in Depressed Patients?. Journal of Clinical Psychiatry, 2001, 62, 776-781.	2.2	53
224	Age-Related Characteristics of Depression: A Preliminary STAR*D Report. American Journal of Geriatric Psychiatry, 2005, 13, 852-860.	1.2	52
225	Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophrenia Research, 2006, 86, 244-250.	2.0	52
226	Is there a role for continuation phase cognitive therapy for depressed outpatients?. Journal of Consulting and Clinical Psychology, 1998, 66, 1036-1040.	2.0	51
227	Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression. Journal of Clinical Psychiatry, 2018, 79, .	2.2	51
228	Folate and Unipolar Depression. Journal of Alternative and Complementary Medicine, 2008, 14, 277-285.	2.1	50
229	Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.. Journal of Consulting and Clinical Psychology, 2008, 76, 459-467.	2.0	50
230	Do atypical features affect outcome in depressed outpatients treated with citalopram?. International Journal of Neuropsychopharmacology, 2010, 13, 15.	2.1	50
231	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results. Psychiatric Services, 2009, 60, 1446-57.	2.0	50
232	Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. Experimental Neurology, 2009, 219, 36-43.	4.1	49
233	A pilot study of the treatment of outpatients with chronic pain: Symptom control, stimulus control and social system intervention. Pain, 1978, 5, 163-172.	4.2	48
234	The Relationship between Serum Prolactin Level and Sexual Functioning among Male Outpatients with Schizophrenia or Schizoaffective Disorder: A Randomized Double-Blind Trial of Risperidone vs. Quetiapine. Journal of Sex and Marital Therapy, 2007, 33, 203-216.	1.5	48

#	Article	IF	Citations
235	DSM Melancholic Features Are Unreliable Predictors of ECT Response. Journal of ECT, 2007, 23, 139-146.	0.6	47
236	Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. Journal of Psychiatric Research, 2007, 41, 239-246.	3.1	47
237	The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. Menopause, 2010, 17, 828-839.	2.0	47
238	When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. American Journal of Psychiatry, 2018, 175, 1176-1184.	7.2	47
239	Compliance With Pharmacotherapy in Mood Disorders. Psychiatric Annals, 1995, 25, 269-279.	0.1	47
240	Texas Medication Algorithm Project. Journal of Clinical Psychiatry, 2001, 62, 439-447.	2.2	47
241	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Translational Psychiatry, 2021, 11, 153.	4.8	46
242	Plasma GABA predicts acute response to divalproex in mania. Biological Psychiatry, 1996, 39, 278-284.	1.3	45
243	Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline. Neuropsychopharmacology, 2001, 25, 131-138.	5.4	45
244	Prevalence of Incompletely Penetrant Huntington's Disease Alleles Among Individuals With Major Depressive Disorder. American Journal of Psychiatry, 2010, 167, 574-579.	7.2	45
245	Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. Journal of Affective Disorders, 2011, 133, 467-476.	4.1	45
246	Measurement‐based care using DSM‐5 for opioid use disorder: can we make opioid medication treatment more effective?. Addiction, 2019, 114, 1346-1353.	3.3	45
247	Differential Effects of Nefazodone and Cognitive Behavioral Analysis System of Psychotherapy on Insomnia Associated With Chronic Forms of Major Depression. Journal of Clinical Psychiatry, 2002, 63, 493-500.	2.2	45
248	National institute of mental health workshop report on the treatment of bipolar disorder. Biological Psychiatry, 1996, 40, 215-220.	1.3	44
249	Therapist Variables That Predict Symptom Change in Psychotherapy With Chronically Depressed Outpatients.. Psychotherapy, 2004, 41, 255-265.	1.2	44
250	An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder. Journal of Psychiatric Practice, 2008, 14, 271-280.	0.7	44
251	On the psychometric validity of the domains of the PDSQ: An illustration of the bi-factor item response theory model. Journal of Psychiatric Research, 2009, 43, 401-410.	3.1	44
252	Income and attrition in the treatment of depression: a STAR*D report. Depression and Anxiety, 2009, 26, 622-633.	4.1	44

#	Article	IF	Citations
253	Impact of Structured Clinical Interviews on Physicians' Practices in Community Mental Health Settings. Psychiatric Services, 2003, 54, 712-718.	2.0	43
254	Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychological Medicine, 2005, 35, 1695-1706.	4.5	43
255	Age-Related Characteristics of Depression: A Preliminary STAR*D Report. American Journal of Geriatric Psychiatry, 2005, 13, 852-860.	1.2	43
256	The Treatment of Chronic Depression, Part 1. Journal of Clinical Psychiatry, 1998, 59, 589-597.	2.2	43
257	Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. Biological Psychiatry, 1995, 37, 806-810.	1.3	42
258	Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. Clinical Trials, 2004, 1, 387-398.	1.6	42
259	Naltrexone in patients with bipolar disorder and alcohol dependence. Depression and Anxiety, 2006, 23, 492-495.	4.1	42
260	Recursive Subsetting to Identify Patients in the STAR*D. Journal of Clinical Psychiatry, 2010, 71, 1502-1508.	2.2	42
261	A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in Patients with Bipolar Disorder, Mixed or Depressed Phase, and Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2014, 38, 2113-2118.	2.4	41
262	Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. American Journal of Psychiatry, 2016, 173, 481-490.	7.2	41
263	Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. Bipolar Disorders, 2001, 3, 23-29.	1.9	40
264	An Open-Label Trial of Quetiapine for Antipsychotic-Induced Sexual Dysfunction. Journal of Sex and Marital Therapy, 2004, 30, 325-332.	1.5	40
265	A Psychometric Evaluation of the CDRS and MADRS in Assessing Depressive Symptoms in Children. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 1204-1212.	0.5	40
266	Treatment Outcomes for Older Depressed Patients With Earlier Versus Late Onset of First Depressive Episode: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Report. American Journal of Geriatric Psychiatry, 2008, 16, 58-64.	1.2	40
267	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. American Journal of Psychiatry, 2016, 173, 1196-1204.	7.2	40
268	What moderator characteristics are associated with better prognosis for depression?. Neuropsychiatric Disease and Treatment, 2005, 1, 51-57.	2.2	40
269	The Stanley Foundation Bipolar Network. British Journal of Psychiatry, 2001, 178, s177-s183.	2.8	39
270	Rethinking funding priorities in mental health research. British Journal of Psychiatry, 2016, 208, 507-509.	2.8	39

#	Article	IF	Citations
271	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. Psychotherapy and Psychosomatics, 2018, 87, 285-295.	8.8	39
272	Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. American Journal of Psychiatry, 2019, 176, 358-366.	7.2	39
273	Does the Duration of Index Episode Affect the Treatment Outcome of Major Depressive Disorder?. Journal of Clinical Psychiatry, 2008, 69, 1246-1256.	2.2	39
274	The effects of vagus nerve stimulation on sleep EEG in depression. Journal of Psychosomatic Research, 2003, 54, 475-482.	2.6	37
275	Constructing evidence-based treatment strategies using methods from computer science. Drug and Alcohol Dependence, 2007, 88, S52-S60.	3.2	37
276	Improving Depression Outcome by Patient-Centered Medical Management. American Journal of Psychiatry, 2018, 175, 1187-1198.	7.2	37
277	Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature. Scientific Reports, 2021, 11, 21011.	3.3	37
278	Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. Journal of Psychopharmacology, 2012, 26, 360-367.	4.0	36
279	Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: Implications for the Research Domain Criteria (RDoC). Journal of Affective Disorders, 2014, 163, 18-24.	4.1	36
280	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. Journal of Affective Disorders, 2020, 264, 90-97.	4.1	36
281	Diurnal Mood Variation in Outpatients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2007, 68, 1339-1347.	2.2	36
282	Clinical and Sociodemographic Characteristics Associated with Suicidal Ideation in Depressed Outpatients. Canadian Journal of Psychiatry, 2013, 58, 113-122.	1.9	35
283	A New Empirical Definition of Major Depressive Episode Recovery and Its Positive Impact on Future Course of Illness. Journal of Clinical Psychiatry, 2016, 77, 1065-1073.	2.2	35
284	Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of its reliability and predictive validity. Psychiatry Research, 2008, 157, 259-263.	3.3	34
285	The Quick Inventory of Depressive Symptomatology-Self-report: a psychometric evaluation in patients with asthma and major depressive disorder. Annals of Allergy, Asthma and Immunology, 2008, 100, 433-438.	1.0	34
286	Do Menopausal Status and Use of Hormone Therapy Affect Antidepressant Treatment Response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. Journal of Women's Health, 2013, 22, 121-131.	3.3	34
287	Clinical research challenges posed by difficult-to-treat depression. Psychological Medicine, 2022, 52, 419-432.	4.5	34
288	Making clinicians lives easier: Guidance on use of the QIDS self-report in place of the MADRS. Journal of Affective Disorders, 2006, 95, 115-118.	4.1	33

#	Article	IF	Citations
289	Depression Treatment in Patients With General Medical Conditions: Results From the CO-MED Trial. Annals of Family Medicine, 2012, 10, 23-33.	1.9	33
290	VitalSign6: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression. Pharmaceuticals, 2019, 12, 71.	3.8	33
291	Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. Translational Psychiatry, 2021, 11, 417.	4.8	33
292	Symptomatic and Syndromal Anxiety in Chronic Forms of Major Depression. Journal of Clinical Psychiatry, 2002, 63, 434-441.	2.2	33
293	The Efficacy of Acute Electroconvulsive Therapy in Atypical Depression. Journal of Clinical Psychiatry, 2008, 69, 406-411.	2.2	33
294	Metabolomic and inflammatory signatures of symptom dimensions in major depression. Brain, Behavior, and Immunity, 2022, 102, 42-52.	4.1	33
295	Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients. Psychiatry Research, 1994, 52, 327-339.	3.3	32
296	Bupropion in the Treatment of Outpatients with Asthma and Major Depressive Disorder. International Journal of Psychiatry in Medicine, 2007, 37, 23-28.	1.8	32
297	Isn't It About Time to Employ Measurement-Based Care in Practice?. American Journal of Psychiatry, 2015, 172, 934-936.	7.2	32
298	Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality. Journal of Affective Disorders, 2018, 235, 45-51.	4.1	32
299	A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. Annals of Family Medicine, 2019, 17, 326-335.	1.9	32
300	Escitalopram in clinical practice: Results of an open-label trial in a naturalistic setting. Depression and Anxiety, 2005, 21, 26-32.	4.1	31
301	Star-D: lessons learned and future implications. Depression and Anxiety, 2011, 28, 521-524.	4.1	31
302	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. American Journal of Nephrology, 2019, 50, 37-47.	3.1	31
303	Age-adjusted threshold values for reduced REM latency in unipolar depression using ROC analysis. Biological Psychiatry, 1990, 27, 841-853.	1.3	30
304	Major Depressive Disorder and Comorbid Cardiac Disease: Is There a Depressive Subtype With Greater Cardiovascular Morbidity? Results From the STAR*D Study. Psychosomatics, 2007, 48, 418-425.	2.5	30
305	A Comparison of the QIDS-C$_{16}$, QIDS-SR$_{16}$, and the MADRS in an Adult Outpatient Clinical Sample. CNS Spectrums, 2010, 15, 458-468.	1.2	30
306	Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial. Psychiatric Services, 2011, 62, 1167-1179.	2.0	30

#	Article	IF	Citations
307	Evaluation of the Effects of Severe Depression on Global Cognitive Function and Memory. CNS Spectrums, 2010, 15, 304-313.	1.2	29
308	Prediction of Nonremission to Antidepressant Therapy Using Diffusion Tensor Imaging. Journal of Clinical Psychiatry, 2016, 77, e436-e443.	2.2	29
309	Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacology Bulletin, 2003, 37, 73-87.	0.0	29
310	Depression and Dexamethasone Suppression Testing in Children and Adolescents. Journal of Child Neurology, 1987, 2, 31-37.	1.4	28
311	Effect of two prednisone exposures on mood and declarative memory. Neurobiology of Learning and Memory, 2006, 86, 28-34.	1.9	28
312	Remission of maternal depression and child symptoms among single mothers. Social Psychiatry and Psychiatric Epidemiology, 2007, 42, 962-971.	3.1	28
313	Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR*D trial. Depression and Anxiety, 2009, 26, 612-621.	4.1	28
314	Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder. Depression and Anxiety, 2017, 34, 1116-1122.	4.1	28
315	Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. Journal of Affective Disorders, 2018, 238, 1-7.	4.1	28
316	Therapeutic Reactance as a Predictor of Outcome in the Treatment of Chronic Depression.. Journal of Consulting and Clinical Psychology, 2003, 71, 1025-1035.	2.0	27
317	Comparison of Quality of Life Measures in a Depressed Population. Journal of Nervous and Mental Disease, 2007, 195, 219-225.	1.0	27
318	Personalizing antidepressant choice by sex, body mass index, and symptom profile: An iSPOT-D report. Personalized Medicine in Psychiatry, 2017, 1-2, 65-73.	0.1	27
319	Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale. International Journal of Neuropsychopharmacology, 2018, 21, 325-332.	2.1	27
320	Implementing Guidelines and Systems of Care. Journal of Psychiatric Practice, 1999, 5, 75-86.	0.7	26
321	Catching Up on Health Outcomes: The Texas Medication Algorithm Project. Health Services Research, 2003, 38, 311-331.	2.0	26
322	Characteristics of Insured and Noninsured Outpatients With Depression in STAR*D. Psychiatric Services, 2005, 56, 995-1004.	2.0	26
323	Daily process methodology for measuring earlier antidepressant response. Contemporary Clinical Trials, 2008, 29, 867-877.	1.8	26
324	Depression Outcomes of Spanish- and English-Speaking Hispanic Outpatients in STAR*D. Psychiatric Services, 2008, 59, 1273-1284.	2.0	26

#	Article	IF	Citations
325	The impact of diabetes on depression treatment outcomes. General Hospital Psychiatry, 2010, 32, 33-41.	2.4	26
326	Combining Antidepressant Medications: A Good Idea?. American Journal of Psychiatry, 2010, 167, 241-243.	7.2	26
327	What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?. Depression and Anxiety, 2012, 29, 94-101.	4.1	26
328	Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). Contemporary Clinical Trials, 2013, 34, 136-144.	1.8	26
329	Adherence to Antidepressant Combinations and Monotherapy for Major Depressive Disorder. Journal of Psychiatric Practice, 2014, 20, 118-132.	0.7	26
330	Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. Journal of Affective Disorders, 2016, 206, 17-22.	4.1	26
331	Perception of Stigma and Its Associated Factors Among Patients With Major Depressive Disorder: A Multicenter Survey From an Asian Population. Frontiers in Psychiatry, 2019, 10, 321.	2.6	26
332	Childhood maltreatment and impact on clinical features of major depression in adults. Psychiatry Research, 2020, 293, 113412.	3.3	26
333	Which Depressed Patients Respond to Nefazodone and When?. Journal of Clinical Psychiatry, 2001, 62, 158-163.	2.2	26
334	Identifying Risk for Attrition during Treatment for Depression. Psychotherapy and Psychosomatics, 2009, 78, 372-379.	8.8	25
335	Predictors of Attrition During One Year of Depression Treatment: A Roadmap to Personalized Intervention. Journal of Psychiatric Practice, 2009, 15, 113-124.	0.7	25
336	The Impact of Chronic Depression on Acute and Long-Term Outcomes in a Randomized Trial Comparing Selective Serotonin Reuptake Inhibitor Monotherapy Versus Each of 2 Different Antidepressant Medication Combinations. Journal of Clinical Psychiatry, 2012, 73, 967-976.	2.2	25
337	Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial. Psychiatry Research, 2008, 159, 115-120.	3.3	24
338	A Brief Clinical Tool to Estimate Individual Patients' Risk of Depressive Relapse Following Remission: Proof of Concept. American Journal of Psychiatry, 2016, 173, 1140-1146.	7.2	24
339	The Texas Medication Algorithm Project Patient and Family Education Program. Journal of Clinical Psychiatry, 2000, 61, 477-486.	2.2	24
340	Measuring costs of guideline-driven mental health care: the Texas Medication Algorithm Project. , 1999, 2, 111-121.		23
341	Diurnal mood variation in outpatients with major depressive disorder. Depression and Anxiety, 2009, 26, 851-863.	4.1	23
342	The Clinical Relevance of Self-Reported Premenstrual Worsening of Depressive Symptoms in the Management of Depressed Outpatients: A STAR*D Report. Journal of Women's Health, 2013, 22, 219-229.	3.3	23

#	Article	IF	Citations
343	Ketamine for Treatment-Resistant Depression: Ready or Not for Clinical Use?. American Journal of Psychiatry, 2013, 170, 1079-1081.	7.2	23
344	Can a Framework Be Established for the Safe Use of Ketamine?. American Journal of Psychiatry, 2018, 175, 587-589.	7.2	23
345	Can psychological features predict antidepressant response to rTMS? A Discovery–Replication approach. Psychological Medicine, 2020, 50, 264-272.	4.5	23
346	Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression. Acta Psychiatrica Scandinavica, 2021, 143, 253-263.	4.5	23
347	Enhancing the Technology of Clinical Trials and the Trials Model to Evaluate Newly Developed, Targeted Antidepressants. Neuropsychopharmacology, 2002, 27, 319-328.	5.4	22
348	Clinical features of depression in Asia: Results of a large prospective, cross-sectional study. Asia-Pacific Psychiatry, 2013, 5, 259-267.	2.2	22
349	Toward an online cognitive and emotional battery to predict treatment remission in depression. Neuropsychiatric Disease and Treatment, 2015, 11, 517.	2.2	22
350	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. Depression and Anxiety, 2020, 37, 771-783.	4.1	22
351	A Pilot Study of an Electronic, Adolescent Version of the Quick Inventory of Depressive Symptomatology. Journal of Clinical Psychiatry, 2007, 68, 1436-1440.	2.2	22
352	Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. Journal of Clinical Psychiatry, 2005, 66, 159-66; quiz 147, 273-4.	2.2	22
353	Enrolling research subjects from clinical practice: Ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) trial. Psychiatry Research, 2006, 141, 193-200.	3.3	21
354	Early Adverse Events and Attrition in Selective Serotonin Reuptake Inhibitor Treatment. Journal of Clinical Psychopharmacology, 2010, 30, 259-266.	1.4	21
355	Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. International Journal of Neuropsychopharmacology, 2012, 15, 1387-1399.	2.1	21
356	Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 803-813.	2.2	21
357	Algorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness. Pharmacopsychiatry, 2019, 52, 117-125.	3.3	21
358	Efficacy, safety, and indications for tricyclic and newer antidepressants. Depression, 1994, 2, 127-137.	0.6	20
359	Electronic source materials in clinical research: Acceptability and validity of symptom self-rating in major depressive disorder. Journal of Psychiatric Research, 2007, 41, 737-743.	3.1	20
360	The Quick Inventory of Depressive Symptomatology (Clinician and Self-Report Versions) in Patients With Bipolar Disorder. CNS Spectrums, 2010, 15, 367-373.	1.2	20

#	Article	IF	Citations
361	Gender-specific structural abnormalities in major depressive disorder revealed by fixel-based analysis. NeuroImage: Clinical, 2019, 21, 101668.	2.7	20
362	EEG biomarker informed prescription of antidepressants in MDD: a feasibility trial. European Neuropsychopharmacology, 2021, 44, 14-22.	0.7	20
363	Cognitive Therapy of Depression: Rationale, Techniques, and Efficacy. Psychiatric Clinics of North America, 1983, 6, 105-127.	1.3	20
364	The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry. International Journal of Bipolar Disorders, 2020, 8, 13.	2.2	20
365	Secular trend in unipolar depression: a hypothesis. Journal of Affective Disorders, 1989, 16, 71-75.	4.1	19
366	Impulsivity and neuroendocrine response to buspirone in bulimia nervosa. Biological Psychiatry, 1996, 39, 371-374.	1.3	19
367	Development of the Brief Bipolar Disorder Symptom Scale for patients with bipolar disorder. Psychiatry Research, 2004, 127, 137-145.	3.3	19
368	An Empirical Analysis of Cost Outcomes of the Texas Medication Algorithm Project. Psychiatric Services, 2006, 57, 648-659.	2.0	19
369	Screening for Major Depression in Private Practice. Journal of Psychiatric Practice, 2009, 15, 87-94.	0.7	19
370	Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: A CO-MED report. Journal of Affective Disorders, 2015, 174, 157-164.	4.1	19
371	Speculations on the Future of Psychiatric Diagnosis. Journal of Nervous and Mental Disease, 2018, 206, 481-487.	1.0	19
372	Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders. Biological Psychiatry, 2002, 52, 631-654.	1.3	18
373	A psychometric evaluation of the clinician†rated Quick Inventory of Depressive Symptomatology (QIDS†C$_{16}$) in patients with bipolar disorder. International Journal of Methods in Psychiatric Research, 2009, 18, 138-146.	2.1	18
374	Outcome measures of depression.. , 0, , 191-245.		18
375	Implementation of the Texas Medication Algorithm Project Patient and Family Education Program. Journal of Clinical Psychiatry, 2006, 67, 1362-1372.	2.2	18
376	Tricyclics and newer antidepressant medications: Treatment options for treatment†resistant depressions. Depression, 1994, 2, 152-168.	0.6	17
377	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Focus (American Psychiatric Publishing), 2008, 6, 128-142.	0.8	17
378	RETENTION AND ATTRITION AMONG AFRICAN AMERICANS IN THE STAR*D STUDY: WHAT CAUSES RESEARCH VOLUNTEERS TO STAY OR STRAY?. Depression and Anxiety, 2013, 30, 1137-1144.	4.1	17

#	Article	IF	Citations
379	Structured Interview and Uniform Assessment Improves Diagnostic Reliability. Journal of Child and Adolescent Psychopharmacology, 2000, 10, 119-131.	1.3	16
380	Family history of completed suicide and characteristics of major depressive disorder: A STARâŽD (sequenced treatment alternatives to relieve depression) study. Journal of Affective Disorders, 2008, 108, 129-134.	4.1	16
381	Changes in Depressive Symptoms and Social Functioning in the Sequenced Treatment Alternatives to Relieve Depression Study. Journal of Nervous and Mental Disease, 2011, 199, 807-810.	1.0	16
382	Assessing anxious features in depressed outpatients. International Journal of Methods in Psychiatric Research, 2011, 20, e69-82.	2.1	16
383	Impairment and distress patterns distinguishing the melancholic depression subtype: An iSPOT-D report. Journal of Affective Disorders, 2015, 174, 493-502.	4.1	16
384	Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. Journal of Affective Disorders, 2019, 246, 62-68.	4.1	16
385	Distinguishing Functional From Syndromal Recovery: Implications for Clinical Care and Research. Journal of Clinical Psychiatry, 2015, 76, e832-e834.	2.2	16
386	Psychiatric Emergency Service Use After Implementation of Managed Care in a Public Mental Health System. Psychiatric Services, 2005, 56, 691-698.	2.0	15
387	Assessing the preventive effects of cognitive therapy following relief of depression: A methodological innovation. Journal of Affective Disorders, 2007, 104, 251-261.	4.1	15
388	A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: A STARâŽD report. Journal of Affective Disorders, 2008, 108, 113-120.	4.1	15
389	The Relationship Between Adverse Events During Selective Serotonin Reuptake Inhibitor Treatment for Major Depressive Disorder and Nonremission in the Suicide Assessment Methodology Study. Journal of Clinical Psychopharmacology, 2011, 31, 31-38.	1.4	15
390	EFFECT OF CONCURRENT SUBSTANCE USE DISORDER ON THE EFFECTIVENESS OF SINGLE AND COMBINATION ANTIDEPRESSANT MEDICATIONS FOR THE TREATMENT OF MAJOR DEPRESSION: AN EXPLORATORY ANALYSIS OF A SINGLE-BLIND RANDOMIZED TRIAL. Depression and Anxiety, 2012, 29, 111-122.	4.1	15
391	Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. Frontiers in Neuroscience, 2019, 13, 926.	2.8	15
392	A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult to treat depression: A novel design for a novel treatment. Contemporary Clinical Trials, 2020, 95, 106066.	1.8	15
393	Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. Journal of Clinical Psychiatry, 2007, 68, 1339-47.	2.2	15
394	Neutrophil β 2 -adrenergic receptor coupling efficiency to Gs protein in subjects with post-traumatic stress disorder and normal controls. Psychopharmacology, 1999, 143, 131-140.	3.1	14
395	Psychotherapies for Depressive Disorders: A Review. , 2001, , 161-232.		14
396	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. Journal of Psychiatric Research, 2018, 102, 65-71.	3.1	14

#	Article	IF	Citations
397	Toward a very brief quality of life enjoyment and Satisfaction Questionnaire. Journal of Affective Disorders, 2019, 242, 87-95.	4.1	14
398	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2020, 126, 19-25.	3.1	14
399	Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. Neuropsychopharmacology, 2021, 46, 1272-1282.	5.4	14
400	Effect of Structured Interviews on Evaluation Time in Pediatric Community Mental Health Settings. Psychiatric Services, 2005, 56, 1098-1103.	2.0	13
401	A Clinician's Perspective on Biomarkers. Focus (American Psychiatric Publishing), 2018, 16, 124-134.	0.8	13
402	New Designs for Studies of the Prophylaxis of Bipolar Disorder. Journal of Clinical Psychopharmacology, 2002, 22, 1-3.	1.4	13
403	Are Depressed Outpatients With and Without a Family History of Substance Use Disorder Different?. Journal of Clinical Psychiatry, 2007, 68, 1931-1938.	2.2	13
404	Platelet α 2 -adrenergic receptor coupling efficiency to G i protein in subjects with post-traumatic stress disorder and normal controls. Psychopharmacology, 1999, 141, 258-266.	3.1	12
405	The Therapeutic Alliance and CBASP-Specific Skill Acquisition in the Treatment of Chronic Depression. Cognitive Therapy and Research, 2005, 29, 803-817.	1.9	12
406	Does Pretreatment Insomnia or Anxiety Predict Acute Response to Bupropion SR?. Annals of Clinical Psychiatry, 2005, 17, 1-9.	0.6	12
407	The Edinburgh Postnatal Depression Scale as a measure for antenatal dysphoria. Journal of Reproductive and Infant Psychology, 2015, 33, 28-41.	1.8	12
408	Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. Neuropsychopharmacology, 2018, 43, 2197-2203.	5.4	12
409	Item response analysis of the inventory of depressive symptomatology. Neuropsychiatric Disease and Treatment, 2006, 2, 557-564.	2.2	12
410	Clinically Relevant Findings from STAR*D. Psychiatric Annals, 2008, 38, .	0.1	12
411	NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data. BMJ Open, 2022, 12, e057227.	1.9	12
412	The Impact of Nonclinical Factors on Care Use for Patients with Depression: A STAR*D Report. CNS Neuroscience and Therapeutics, 2009, 15, 320-332.	3.9	11
413	Measuring Use and Cost of Care for Patients With Mood Disorders. Medical Care, 2009, 47, 184-190.	2.4	11
414	Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. Journal of Psychiatric Research, 2013, 47, 1199-1203.	3.1	11

#	Article	IF	Citations
415	Estimating Optimal Shared-Parameter Dynamic Regimens with Application to a Multistage Depression Clinical Trial. Biometrics, 2016, 72, 865-876.	1.4	11
416	Factors Associated with Concomitant Psychotropic Drug Use in the Treatment of Major Depression: A STAR*D Report. CNS Spectrums, 2009, 14, 487-498.	1.2	10
417	Setting Measurement-Based Care in Motion: Practical Lessons in the Implementation and Integration of Measurement-Based Care in Psychiatry Clinical Practice. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1621-1631.	2.2	10
418	Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression. Journal of Affective Disorders, 2022, 307, 254-263.	4.1	10
419	Strategies for Implementing Psychiatric Medication Algorithms in the Public Sector. Journal of Psychiatric Practice, 1999, 5, 32-36.	0.7	9
420	A Quality Improvement Process for Implementing the Texas Algorithm for Schizophrenia in Ohio. Psychiatric Services, 2003, 54, 1646-1649.	2.0	9
421	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. Australian and New Zealand Journal of Psychiatry, 2009, 43, 956-967.	2.3	9
422	Performance of depression rating scales in patients with chronic kidney disease: an item response theory-based analysis. General Hospital Psychiatry, 2016, 42, 60-66.	2.4	9
423	Toward a very brief self‐report to assess the core symptoms of depression (VQIDS‐SR$_5$). Acta Psychiatrica Scandinavica, 2017, 135, 548-553.	4.5	9
424	Narrowing the Gaps Between What We Know and What We Do in Psychiatry. Journal of Clinical Psychiatry, 2015, 76, 1366-1372.	2.2	9
425	Desipramine Versus Phenelzine in Recurrent Unipolar Depression. Journal of Clinical Psychopharmacology, 1997, 17, 78-83.	1.4	8
426	<p>The Long and Winding Road of Vagus Nerve Stimulation: Challenges in Developing an Intervention for Difficult-to-Treat Mood Disorders</p>. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 3081-3093.	2.2	8
427	Natural Language Processing-Based Quantication of the Mental State of Psychiatric Patients. Computational Psychiatry, 2020, 4, 76.	2.0	8
428	Naturalistic study of the early psychiatric use of citalopram in the United States. Depression and Anxiety, 2002, 16, 121-127.	4.1	7
429	Pretreatment Correlates of the Therapeutic Alliance in the Chronically Depressed. Journal of Contemporary Psychotherapy, 2002, 32, 281-290.	1.2	7
430	Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). Journal of Psychiatric Research, 2004, 38, 241-248.	3.1	7
431	Development of a computerized assessment of clinician adherence to a treatment guideline for patients with bipolar disorder. Journal of Psychiatric Research, 2004, 38, 285-294.	3.1	7
432	Developing the evidence for evidence-based practice. Cmaj, 2008, 178, 1313-1315.	2.0	7

#	Article	IF	Citations
433	Data-driven longitudinal modeling and prediction of symptom dynamics in major depressive disorder: Integrating factor graphs and learning methods. , 2017, , .		7
434	Screening for panic-related anxiety in emergency department patients with cardiopulmonary complaints: A comparison of two self-report instruments. Psychiatry Research, 2018, 263, 7-14.	3.3	7
435	Clinical Implications of the STAR*D Trial. Handbook of Experimental Pharmacology, 2018, 250, 51-99.	1.8	7
436	A Brief Interview to Detect Panic Attacks and Panic Disorder in Emergency Department Patients with Cardiopulmonary Complaints. Journal of Psychiatric Practice, 2018, 24, 32-44.	0.7	7
437	Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials. International Journal of Neuropsychopharmacology, 2019, 22, 339-348.	2.1	7
438	The Concise Health Risk Tracking Self‐Report (CHRT‐SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. Depression and Anxiety, 2019, 36, 313-320.	4.1	7
439	Using the NIH Research, Condition and Disease Categorization Database for research advocacy: Schizophrenia research at NIMH as an example. PLoS ONE, 2020, 15, e0241062.	2.5	7
440	Practice guidelines in mental health and addiction services: contributions from the American College of Mental Health Administration. Administration and Policy in Mental Health and Mental Health Services Research, 2002, 30, 21-33.	2.1	6
441	Clinician ratings vs. global ratings of symptom severity: a comparison of symptom measures in the bipolar disorder module, phase II, Texas Medication Algorithm Project. Psychiatry Research, 2003, 117, 167-175.	3.3	6
442	The Implementation of Cognitive Therapy in STAR*D. Cognitive Therapy and Research, 2004, 28, 819-833.	1.9	6
443	Quality improvement methods as applied to a multicenter effectiveness trial—STAR*D. Contemporary Clinical Trials, 2005, 26, 95-112.	1.8	6
444	Psychotherapy of the affective psychoses. American Journal of Psychoanalysis, 1980, 40, 99-123.	0.4	5
445	Polysomnogram in major depressive and obsessive‐compulsive disorders: A preliminary study. Depression, 1994, 2, 297-302.	0.6	5
446	Validation of the Inventory of Depressive Symptomatology (IDS) in Cocaine Dependent Inmates. Journal of Offender Rehabilitation, 2001, 32, 15-30.	0.8	5
447	Dr. Trivedi and Colleagues Reply. American Journal of Psychiatry, 2006, 163, 1293-1294.	7.2	5
448	Insured and Non-insured Depressed Outpatients: How Do They Compare?. Annals of Clinical Psychiatry, 2007, 19, 73-82.	0.6	5
449	The role of efficacy and effectiveness trials. World Psychiatry, 2009, 8, 34-35.	10.4	5
450	Impact of childhood maltreatment on outcomes of antidepressant medication in chronic and/or recurrent depression. Journal of Affective Disorders, 2021, 291, 39-45.	4.1	5

#	Article	IF	Citations
451	Differential Responses to Psychotherapy Versus Pharmacotherapy in Patients With Chronic Forms of Major Depression and Childhood Trauma. Focus (American Psychiatric Publishing), 2005, 3, 131-135.	0.8	4
452	Effects of heart disease on depression treatment: results from the COMED study. General Hospital Psychiatry, 2012, 34, 24-34.	2.4	4
453	Variable and threshold selection to control predictive accuracy in logistic regression. Journal of the Royal Statistical Society Series C: Applied Statistics, 2014, 63, 657-672.	1.0	4
454	The need for paediatric registries to assess long-term brain effects of psychotropic medications: The case of bipolar disorder. European Neuropsychopharmacology, 2018, 28, 1181-1184.	0.7	4
455	The Effectiveness of Antidepressant Monotherapy in a Naturalistic Outpatient Setting. primary care companion for CNS disorders, The, 2012, 14, .	0.6	4
456	Anterior cingulate cortex in individuals with depressive symptoms: A structural MRI study. Psychiatry Research - Neuroimaging, 2022, 319, 111420.	1.8	4
457	Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia. International Journal of Methods in Psychiatric Research, 2002, 11, 45-53.	2.1	3
458	Dr. McGrath and Colleagues Reply. American Journal of Psychiatry, 2007, 164, 524-524.	7.2	3
459	Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression. Focus (American Psychiatric Publishing), 2008, 6, 69-79.	0.8	3
460	Engaging Depressed Patients: An Essential Step in Optimizing Care. American Journal of Psychiatry, 2017, 174, 506-507.	7.2	3
461	Targeting treatments for depression: what can our patients tell us?. Epidemiology and Psychiatric Sciences, 2017, 26, 37-39.	3.9	3
462	Accurately identifying patients who are excellent candidates or unsuitable for a medication: a novel approach. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 3001-3010.	2.2	3
463	The Adolescent Resilience Questionnaire: Validation of a Shortened Version in U.S. Youths. Frontiers in Psychology, 2020, 11, 606373.	2.1	3
464	Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. Journal of Affective Disorders, 2021, 282, 602-610.	4.1	3
465	Making Therapy Widely Available: Clinical Research Triumph or Existential Catastrophe?. American Journal of Psychiatry, 2022, 179, 79-82.	7.2	3
466	Voice response system to measure healthcare costs: a STAR*D report. American Journal of Managed Care, 2009, 15, 153-62.	1.1	3
467	Psychometric and Clinical Evaluation of the Clinician (VQIDS-C5) and Self-Report (VQIDS-SR5) Versions of the Very Quick Inventory of Depressive Symptoms. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 289-302.	2.2	3
468	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. Focus (American Psychiatric Publishing), 2008, 6, 104-119.	0.8	2

#	Article	IF	Citations
469	Dr. Rush Replies. American Journal of Psychiatry, 2008, 165, 133-134.	7.2	2
470	Addressing the unmet needs of current antidepressants: does neuroscience help or hinder clinical psychopharmacology research?. Expert Opinion on Pharmacotherapy, 2017, 18, 1417-1420.	1.8	2
471	Psychometric Evaluation of the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire in a General Youth Population. Child Psychiatry and Human Development, 2021, , 1.	1.9	2
472	Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents. Focus (American Psychiatric Publishing), 2008, 6, 348-357.	0.8	1
473	Cognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report. International Journal of Cognitive Therapy, 2009, 2, 66-87.	2.2	1
474	Release bias in accessing medical records in clinical trials: a STAR*D report. International Journal of Methods in Psychiatric Research, 2009, 18, 147-158.	2.1	1
475	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. Focus (American Psychiatric Publishing), 2012, 10, 492-505.	0.8	1
476	What Did STARâœ«D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. Focus (American Psychiatric Publishing), 2012, 10, 510-517.	0.8	1
477	Can the digital revolution improve care for mood disorders patients?. Journal of Affective Disorders, 2021, 282, 1193-1194.	4.1	1
478	Managed Care and the Focus on Outcomes Research. Journal of Psychiatric Practice, 1997, 3, 135-145.	0.7	1
479	Medical Test Development and Implementation: A Multistep Journey. Journal of Clinical Psychiatry, 2015, 76, e220-e221.	2.2	1
480	Dr. Scheffer and Colleagues Reply. American Journal of Psychiatry, 2005, 162, 2197-a-2198.	7.2	0
481	Antecedentes familiares de suicidio consumado y caracterÃsticas del trastorno depresivo mayor: estudio STAR*D (sequenced treatment alternatives to relieve depression). Psiquiatria Biologica, 2008, 15, 195-201.	0.1	0
482	Ketamine for Treatment-Resistant Depression: Ready or Not for Clinical Use?. Focus (American) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22	0.8	0
483	Toward precision medicine for depression: admitting ignorance and focusing on failures. World Psychiatry, 2016, 15, 242-243.	10.4	0
484	2017 in Review. American Journal of Psychiatry, 2017, 174, 1140-1143.	7.2	0
485	2018 in Review. American Journal of Psychiatry, 2018, 175, 1163-1166.	7.2	0
486	Biomarkers: Where Are We Going?. Focus (American Psychiatric Publishing), 2018, 16, 123-123.	0.8	0

#	Article	IF	Citations
487	Do depressed patients with diabetes experience more side effects when treated with CitalopramThan their counterparts without diabetes? a STAR*D study. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 186-96.	0.6	0